Quantisnow Logo
Dashboard

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $EDIT alert in real time by email

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET to discuss results for the fourth quarter and full year 2023 and to provide a corporate update.

To access the conference call:

  • U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins.
  • Participants should ask to be connected to the Editas Medicine Earnings Conference Call.

The conference call will also be webcast and can be accessed from the "Investors" section of the Editas Medicine website at https://www.editasmedicine.com. A replay will be available at the same site approximately one hour after the completion of the call.

In addition to the conference call, management will participate in the following upcoming investor conferences:

  • TD Cowen 44th Annual Health Care Conference

    Format: Fireside Chat

    Date: Monday, March 4

    Time: 12:50 p.m. ET

    Location: Boston, MA
  • Leerink Partners Global Biopharma Conference

    Format: Fireside Chat

    Date: Tuesday, March 12

    Time: 10:40 a.m. ET

    Location: Miami Beach, FL
  • Barclays 26th Annual Global Healthcare Conference

    Format: Fireside Chat

    Date: Wednesday, March 13

    Time: 2:05 p.m. ET

    Location: Miami Beach, FL

To access the live webcasts of Editas Medicine's presentations, please visit the "Investors" section of the Company's website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.

About Editas Medicine

As a clinical-stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.



Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Primary Logo

Get the next $EDIT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EDIT

DatePrice TargetRatingAnalyst
12/16/2024Neutral → Underweight
Analyst
12/13/2024Buy → Neutral
Chardan Capital Markets
12/13/2024Buy → Hold
Truist
12/13/2024$11.00 → $3.00Buy → Hold
Stifel
12/11/2024$7.00 → $4.00Overweight → Equal Weight
Wells Fargo
11/25/2024$13.00 → $1.00Buy → Underperform
BofA Securities
11/6/2024In-line → Outperform
Evercore ISI
11/4/2024Outperform → Mkt Perform
Raymond James
More analyst ratings

$EDIT
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Editas Medicine Announces Chief Financial Officer Transition

    Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy Parison will succeed Mr. Lucera as Chief Financial Officer. "We are thrilled to promote Amy to the executive leadership team as our new CFO. Amy joined Editas two and a half years ago as our head of Finance, working closely with the CFO. Her track record of financia

    $EDIT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

    On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2024 and provided business upd

    $EDIT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

    CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March: TD Cowen 45th Annual Health Care Conference Format: Fireside ChatDate: Monday, March 3Time: 2:30 p.m. ETLocation: Boston, MA Leerink Partners

    $EDIT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$EDIT
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$EDIT
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$EDIT
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$EDIT
 SEC Filings

See more

$EDIT
 Leadership Updates

Live Leadership Updates

See more

  • Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

    CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company's first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine's commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company's current and future pipeline of products. "As we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren's caliber to Editas. Caren has a proven ability to translate early discovery and clinical assets into

    $EDIT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

    Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen

    $EDIT
    $MDNA
    $TNGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

  • Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company's Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas' drug discovery team and activities related to Editas Medicine's pipeline of experimental medicines across all therapeutic areas and indications. "Earlier this year, we shared our vision to be a leader in programable in vivo gene editing, and I couldn't be happier that Linda is joining Editas to help make this vision a reality. Linda has an outstanding track record of inventing or contributing to the fo

    $EDIT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$EDIT
 Financials

Live finance-specific insights

See more

  • Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

    On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2024 and provided business upd

    $EDIT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

    Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humanized mouse model for treatment of sickle cell disease and beta thalassemia with a single dose of an HSC-targeted lipid nanoparticle (tLNP) formulationAchieved in vivo proof of concept of high efficiency editing in the liver in non-human primates Ending development of reni-cel after extensive search did not yield a commercial partner The Company will work closely with the clinical trial sites, regulators, and other parties to determine the path forward for patien

    $EDIT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Editas Medicine Announces Third Quarter 2024 Results and Business Updates

    Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on its in vivo progress and pipeline development in 1Q 2025 Company expects the existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI

    $EDIT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$EDIT
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more